ResMed (NYSE:RMD – Get Free Report) and Jushi (OTCMKTS:JUSHF – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
Analyst Ratings
This is a summary of recent ratings and recommmendations for ResMed and Jushi, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ResMed | 0 | 6 | 8 | 1 | 2.67 |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
ResMed presently has a consensus price target of $273.00, indicating a potential upside of 44.57%. Given ResMed’s higher possible upside, analysts clearly believe ResMed is more favorable than Jushi.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ResMed | $5.15 billion | 5.32 | $1.40 billion | $10.37 | 18.21 |
| Jushi | $262.91 million | 0.36 | -$68.59 million | ($0.36) | -1.33 |
ResMed has higher revenue and earnings than Jushi. Jushi is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ResMed has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Jushi has a beta of -0.71, suggesting that its share price is 171% less volatile than the S&P 500.
Profitability
This table compares ResMed and Jushi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ResMed | 27.44% | 25.35% | 18.69% |
| Jushi | -26.90% | N/A | -16.59% |
Institutional & Insider Ownership
55.0% of ResMed shares are held by institutional investors. Comparatively, 21.7% of Jushi shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 23.1% of Jushi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ResMed beats Jushi on 13 of the 15 factors compared between the two stocks.
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
